Targeted radionuclide therapy

Lawrence E. Williams, Gerald L Denardo, Ruby F. Meredith

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Targeted radionuclide therapy (TRT) seeks molecular and functional targets within patient tumor sites. A number of agents have been constructed and labeled with beta, alpha, and Auger emitters. Radionuclide carriers spanning a broad range of sizes; e.g., antibodies, liposomes, and constructs such as nanoparticles have been used in these studies. Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle. Lymphoma (B-cell) has been the primary clinical application. Extension to solid tumors will require raising the macroscopic absorbed dose by several-fold over values found in present technology. Methods that may effect such changes include multistep targeting, simultaneous chemotherapy, and external sequestration of the agent. Toxicity has primarily involved red marrow so that marrow replacement can also be used to enhance future TRT treatments. Correlation of toxicities and treatment efficiency has been limited by relatively poor absorbed dose estimates partly because of using standard (phantom) organ sizes. These associations will be improved in the future by obtaining patient-specific organ size and activity data with hybrid SPECT/CT and PET/CT scanners.

Original languageEnglish (US)
Pages (from-to)3062-3068
Number of pages7
JournalMedical Physics
Volume35
Issue number7
DOIs
StatePublished - 2008

Fingerprint

Radioisotopes
Organ Size
Bone Marrow
B-Cell Lymphoma
Therapeutics
Liposomes
Nanoparticles
Neoplasms
Technology
Drug Therapy
Antibodies

Keywords

  • Absorbed dose
  • Antibodies
  • Radionuclide therapy

ASJC Scopus subject areas

  • Biophysics
  • Medicine(all)
  • Radiology Nuclear Medicine and imaging

Cite this

Williams, L. E., Denardo, G. L., & Meredith, R. F. (2008). Targeted radionuclide therapy. Medical Physics, 35(7), 3062-3068. https://doi.org/10.1118/1.2938520

Targeted radionuclide therapy. / Williams, Lawrence E.; Denardo, Gerald L; Meredith, Ruby F.

In: Medical Physics, Vol. 35, No. 7, 2008, p. 3062-3068.

Research output: Contribution to journalArticle

Williams, LE, Denardo, GL & Meredith, RF 2008, 'Targeted radionuclide therapy', Medical Physics, vol. 35, no. 7, pp. 3062-3068. https://doi.org/10.1118/1.2938520
Williams, Lawrence E. ; Denardo, Gerald L ; Meredith, Ruby F. / Targeted radionuclide therapy. In: Medical Physics. 2008 ; Vol. 35, No. 7. pp. 3062-3068.
@article{269a7b11454e429abc1ced71ac696671,
title = "Targeted radionuclide therapy",
abstract = "Targeted radionuclide therapy (TRT) seeks molecular and functional targets within patient tumor sites. A number of agents have been constructed and labeled with beta, alpha, and Auger emitters. Radionuclide carriers spanning a broad range of sizes; e.g., antibodies, liposomes, and constructs such as nanoparticles have been used in these studies. Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle. Lymphoma (B-cell) has been the primary clinical application. Extension to solid tumors will require raising the macroscopic absorbed dose by several-fold over values found in present technology. Methods that may effect such changes include multistep targeting, simultaneous chemotherapy, and external sequestration of the agent. Toxicity has primarily involved red marrow so that marrow replacement can also be used to enhance future TRT treatments. Correlation of toxicities and treatment efficiency has been limited by relatively poor absorbed dose estimates partly because of using standard (phantom) organ sizes. These associations will be improved in the future by obtaining patient-specific organ size and activity data with hybrid SPECT/CT and PET/CT scanners.",
keywords = "Absorbed dose, Antibodies, Radionuclide therapy",
author = "Williams, {Lawrence E.} and Denardo, {Gerald L} and Meredith, {Ruby F.}",
year = "2008",
doi = "10.1118/1.2938520",
language = "English (US)",
volume = "35",
pages = "3062--3068",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "7",

}

TY - JOUR

T1 - Targeted radionuclide therapy

AU - Williams, Lawrence E.

AU - Denardo, Gerald L

AU - Meredith, Ruby F.

PY - 2008

Y1 - 2008

N2 - Targeted radionuclide therapy (TRT) seeks molecular and functional targets within patient tumor sites. A number of agents have been constructed and labeled with beta, alpha, and Auger emitters. Radionuclide carriers spanning a broad range of sizes; e.g., antibodies, liposomes, and constructs such as nanoparticles have been used in these studies. Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle. Lymphoma (B-cell) has been the primary clinical application. Extension to solid tumors will require raising the macroscopic absorbed dose by several-fold over values found in present technology. Methods that may effect such changes include multistep targeting, simultaneous chemotherapy, and external sequestration of the agent. Toxicity has primarily involved red marrow so that marrow replacement can also be used to enhance future TRT treatments. Correlation of toxicities and treatment efficiency has been limited by relatively poor absorbed dose estimates partly because of using standard (phantom) organ sizes. These associations will be improved in the future by obtaining patient-specific organ size and activity data with hybrid SPECT/CT and PET/CT scanners.

AB - Targeted radionuclide therapy (TRT) seeks molecular and functional targets within patient tumor sites. A number of agents have been constructed and labeled with beta, alpha, and Auger emitters. Radionuclide carriers spanning a broad range of sizes; e.g., antibodies, liposomes, and constructs such as nanoparticles have been used in these studies. Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle. Lymphoma (B-cell) has been the primary clinical application. Extension to solid tumors will require raising the macroscopic absorbed dose by several-fold over values found in present technology. Methods that may effect such changes include multistep targeting, simultaneous chemotherapy, and external sequestration of the agent. Toxicity has primarily involved red marrow so that marrow replacement can also be used to enhance future TRT treatments. Correlation of toxicities and treatment efficiency has been limited by relatively poor absorbed dose estimates partly because of using standard (phantom) organ sizes. These associations will be improved in the future by obtaining patient-specific organ size and activity data with hybrid SPECT/CT and PET/CT scanners.

KW - Absorbed dose

KW - Antibodies

KW - Radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=46149100279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149100279&partnerID=8YFLogxK

U2 - 10.1118/1.2938520

DO - 10.1118/1.2938520

M3 - Article

C2 - 18697529

AN - SCOPUS:46149100279

VL - 35

SP - 3062

EP - 3068

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 7

ER -